Zenas BioPharma, Inc. (ZBIO)
27.48
-2.16
(-7.27%)
USD |
NASDAQ |
Sep 24, 16:00
27.48
0.00 (0.00%)
After-Hours: 19:59
Zenas BioPharma Net Income (Quarterly) : -111.46M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -111.46M |
| March 31, 2026 | -80.99M |
| December 31, 2025 | -240.44M |
| September 30, 2025 | -51.50M |
| June 30, 2025 | -52.22M |
| March 31, 2025 | -33.57M |
| December 31, 2024 | -52.60M |
| Date | Value |
|---|---|
| September 30, 2024 | -38.61M |
| June 30, 2024 | -37.98M |
| March 31, 2024 | -27.80M |
| December 31, 2023 | -24.59M |
| September 30, 2023 | 35.61M |
| June 30, 2023 | -29.05M |
| March 31, 2023 | -19.10M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 1.00M |
| Total Expenses (Quarterly) | 112.46M |
| EPS Diluted (Quarterly) | -1.766 |
| Enterprise Value | 1.623B |
| Gross Profit Margin (Quarterly) | 99.60% |
| Profit Margin (Quarterly) | -11.15K% |
| Earnings Yield | -35.00% |
| Normalized Earnings Yield | -24.35 |